CFT and MMV outcomes
The overtime BCVA improvement with levosulpiride was paralleled by longitudinal upgrades in CFT and MMV. The mean CFT longitudinal change of study eyes declined relative to baseline at weeks 4 to 8 after levosulpiride vs. placebo and accounted for a mean loss of 46.6 μm at the end of treatment (Fig. 